Efficacy and Safety of Ingavirin®, 90 mg Capsules in Patients With COVID-19

PHASE3CompletedINTERVENTIONAL
Enrollment

233

Participants

Timeline

Start Date

October 6, 2021

Primary Completion Date

January 12, 2022

Study Completion Date

April 25, 2022

Conditions
COVID-19
Interventions
DRUG

Ingavirin®, 90 mg capsules

90-180 mg/day for 7 days on top of standard therapy

DRUG

Placebo

1-2 capsules for 7 days on top of standard therapy

Trial Locations (14)

117556

"State Budgetary Institution of Healthcare of Moscow City Polyclinic No. 2 of the Moscow Department of Healthcare", Moscow

119571

Unimed-C Jsc, Moscow

153025

Ivanovo Kuvaev Clinical Hospital, Ivanovo

190013

"Limited Liability Company Medical Center Capital-Policy", Saint Petersburg

195427

"Saint Petersburg State Budgetary Healthcare Institution City polyclinic No. 112", Saint Petersburg

196143

"Limited Liability Company Research Center Eco-Safety", Saint Petersburg

"St. Petersburg State Budgetary Healthcare Institution City Polyclinic No. 117", Saint Petersburg

199106

"Saint Petersburg State Budgetary Institution of Healthcare City Pokrovskaya Hospital", Saint Petersburg

199226

Astarta LLC, Saint Petersburg

346918

"Municipal Budgetary Institution of Healthcare Central City Hospital of Novoshakhtinsk", Novoshakhtinsk

357502

"4D Ultrasound Clinic LLC", Pyatigorsk

390026

Ryazan State Medical University named after Academician I.P. Pavlova, Ryazan

390039

"State Budgetary Institution of the Ryazan Region Regional Clinical Hospital", Ryazan

620102

"Family Clinic LLC", Yekaterinburg

All Listed Sponsors
lead

Valenta Pharm JSC

INDUSTRY

NCT05216497 - Efficacy and Safety of Ingavirin®, 90 mg Capsules in Patients With COVID-19 | Biotech Hunter | Biotech Hunter